Scroll for more

blog

BenevolentAI

As the UK’s leading AI and machine learning technology company, BenevolentAI wants to use this blog to share its thoughts, insight and predictions.

Jun 21, 2018 benevolentai

BenevolentAI Awarded Technology Pioneer Status by World Economic Forum

Every year, the World Economic Forum welcomes leading early-stage technology companies from around the world into its Technology Pioneer’s community. In its own words, these companies are “poised to have a significant impact on business and society”. Today we are delighted and humbled to be named as one such Technology Pioneer.

Jun 11, 2018 benevolentai

The Long Read – Thinking Deep on the Future of AI

Joanna Shields gives the opening speech at CogX 2018 event about "Why AI matters to us all"

Jun 7, 2018 benevolentai

Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005

Clinicaltrials.gov is the world’s largest primary registry of clinical studies. For almost two decades now  it has been helping physicians, patients, and regulators identify relevant trials and collect evidence.

May 2, 2018 benevolentai

A new chapter @ BenevolentAI

Today marks my first official day as Group CEO at BenevolentAI. For me, it is the next step of a journey, one that has encompassed amazing experiences building some of the biggest technology brands on the planet. Yet none of them had the same potential to transform our lives for the better as we have here at BenevolentAI.

Apr 4, 2018 benevolentai

RESEARCH | Organic synthesis provides opportunities to transform drug discovery

Ian Churcher, VP Drug Discovery recently published a paper in Nature to highlight how organic synthesis could represent an opportunity for the pharmaceuticals industries to improve drug development. He presents the current challenges that the industry needs overcome and explains how new technologies and industry-academia collaborations are essential to progress.

Apr 3, 2018 benevolentai

Love drug discovery? You just need the right chemistry!

There is an increasing number of varieties of drug agents in clinical use ranging from antibodies and proteins to nucleic acids and, increasingly, cellular and genetic therapies but the majority of drugs on the market and in development today are still small, synthetic molecules made in a chemistry laboratory.

Mar 29, 2018 benevolentai

RESEARCH | Planning chemical syntheses with deep neural networks and symbolic AI

Marwin Segler, senior machine learning researcher at BenevolentAI, shows in his Nature paper how AI can transform the success rate of planning the synthesis of organic molecules – so-called retrosynthesis.

Mar 27, 2018 benevolentai

RESEARCH | Exploring deep recurrent models with reinforcement learning for molecule design

The design of small molecules with bespoke properties is of central importance to drug discovery. However significant challenges yet remain for computational methods, despite recent advances such as deep recurrent networks and reinforcement learning strategies for sequence generation, and it can be difficult to compare results across different works.

Mar 1, 2018 benevolentai

A view from the labs

A new view brings a new perspective… …its late February and I am sitting in our new Cambridge office looking at an unusually snowy scene of lawns and woodland.

Jan 16, 2018 benevolentai

What if AI could take your research to the next level?

Most scientific breakthroughs are made by analysing data, but we live in a world where the exponential growth of scientific research data makes the discovery of new drugs and treatments for disease very difficult. 

Oct 3, 2017 benevolentai

Are You Looking For A Faster Horse In Drug Discovery?

As we all work busily in our own corners of drug discovery, be it in Pharma, biotech or academia, ask yourself the question – are you just pushing that horse a little more or are you genuinely imagining and creating the model T of the 21st century?

May 31, 2017 benevolentai

Join the special interest group on artificial intelligence in biomedicine.

Initiated after the first Artificial Intelligence (AI) in Bioscience Symposium in 2016, the special interest group on AI in Biomedicine aims at stimulating debate and encouraging collaboration between experts in life science and AI.

Feb 8, 2017 benevolentai

What's in a name? Our first clinical trial

Recently we welcomed the news that we have officially selected a study name for BenevolentAI's first clinical trial.